Amylin, Food Intake, and Obesity
Citations Over TimeTop 13% of 2002 papers
Abstract
Amylin, also known as islet amyloid polypeptide, identified in 1987, is a naturally occurring hormone, released by the beta cells of the pancreas and consists of 37 amino acids. Amylin seems to decrease food intake through both central and peripheral mechanisms and indirectly by slowing gastric emptying. The mean basal amylin concentration is higher in obese than in lean human subjects. The amylin response to oral glucose is also greater in obese subjects, whether or not they have impaired glucose tolerance. The elevated amylin levels in obesity may lead to down-regulation of amylin receptors and lessen the impact of postprandial amylin secretion on satiety and gastric emptying. Amylin administration may overcome resistance at target tissues, delay gastric emptying, and have potential for inducing weight loss in obese individuals.
Related Papers
- → Effect of GLP-1 on gastric volume, emptying, maximum volume ingested, and postprandial symptoms in humans(2002)227 cited
- → Amylin – Its role in the homeostatic and hedonic control of eating and recent developments of amylin analogs to treat obesity(2017)128 cited
- → Comparative effects of amylin and cholecystokinin on food intake and gastric emptying in rats(2001)94 cited
- → Effects of Postprandial Walking on Delayed Gastric Emptying and Intragastric Meal Distribution in Longstanding Diabetics(2000)19 cited
- → Effects of postprandial walking on delayed gastric emptying and intragastric meal distribution in longstanding diabetics(2000)2 cited